Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2020-01-13 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company disclosing a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's current holdings, the planned reduction amount, methods of reduction, timing, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal notification about a shareholder's intention to reduce their stake, which fits the definition of a Major Shareholding Notification (MRQ). The document length is about 3,044 characters, consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2020-01-13 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from a regulatory authority. It includes details about the certificate, product information, and potential impact on company performance. The document is short (767 characters) and does not contain financial statements, detailed financial data, or comprehensive report content. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-01-07 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the progress of cash management using idle funds. It includes specifics about entrusted financial products, amounts, risk control, decision procedures, and financial impacts. The document is not a full financial report but an update on capital management activities, specifically the use of idle funds for purchasing financial products. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not a report publication announcement since it contains substantive details about the transactions and risk controls. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and capital management.
2020-01-06 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the progress of cash management using idle raised funds. It includes specifics about entrusted financial products, amounts, terms, risk control, and the company's internal decision-making process. The document is not a full financial report but rather an update on capital management activities related to fundraising proceeds. It does not contain comprehensive financial statements or quarterly/yearly financial results. The content aligns with updates on company fundraising and capital structure usage rather than earnings, board changes, or legal matters. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (6350 characters) and detailed financial product information support this classification with high confidence.
2020-01-02 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from a regulatory authority (Henan Provincial Drug Administration). It details the certificates obtained, product descriptions, R&D investments, and potential impact on company performance. The document is short (1206 characters) and is an announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a Regulatory Filing (RNS) as a general regulatory announcement about product registration and compliance.
2020-01-01 Chinese
关于控股股东所持公司股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the release of pledged shares held by the controlling shareholder of the company. It details the number of shares released from pledge, the dates, and the shareholder involved. There is no financial report, earnings data, or management discussion. The content is about a change in share pledge status, which relates to capital structure but is specifically about share pledge release rather than new financing or capital raising. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share pledge status and does not fit the more specific categories like Capital/Financing Update (CAP) which usually involves new financing activities. The document is short and focused on a specific disclosure event, typical of RNS filings.
2020-01-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.